论文信息 - New oral anticoagulant drugs - mechanisms of action

New oral anticoagulant drugs - mechanisms of action

Summary in 2008, two new oral anticoagulant drugs were registered in Australia for the prevention of venous thrombosis after elective knee or hip replacement. rivaroxaban is a direct reversible competitive antagonist of activated factor X. dabigatran etexilate is a direct reversible competitive antagonist of thrombin. Both drugs are effective anticoagulants which offer potential advantages over heparin and warfarin.

T. Brighton | Timothy Brighton

[1] A. Verma,et al. The Direct Factor Xa Inhibitor Rivaroxaban , 2022 .

[2] K. Rathgen,et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. , 2007, British journal of clinical pharmacology.